Niraparib and dostarlimab for cancer with growing brain spots
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial studies whether the medicines niraparib and dostarlimab can slow advanced cancers that have active, growing brain metastases. It is meant for people whose brain tumors can be measured on MRI and who have had at least one previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced cancer that has spread to the brain and is actively growing on an MRI.
- Your brain metastases are measurable (about 0.5–3 cm), and you do not have major brain nerve symptoms that are untreated.
- You have had at least one prior cancer treatment that targeted your cancer.
- You can have an MRI (you’re not unsafe with MRI contrast, and you can lie still); you also have a brain MRI with contrast capability.
- You have enough blood counts and organ function on recent lab tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
This trial studies whether pembrolizumab (an immune therapy medicine) plus stereotactic radiosurgery (focused radiation) can better control brain metastases from breast cancer. It may help shrink or slow growth of multiple brain spots with minimal treatment to surrounding tissue.
This trial tests a combination of radiation to the brain, a hormone therapy, and a targeted drug called dalpiciclib for people with advanced breast cancer that has spread to the brain. The goal is to see if this combination can help control the cancer in the brain and elsewhere.
This study is testing a new targeted therapy for people with HER2-positive breast cancer that has spread to the brain. It aims to see if the drug can help shrink brain tumors and improve outcomes for two groups: those with cancer in the fluid around the brain and those without.
This Phase 2 study tests whether combining dostarlimab (an immunotherapy) with niraparib (a cancer pill) can shrink advanced penile cancer and keep it from growing. It may help people whose cancer has progressed after limited prior treatments, and who have not had certain immune therapies before.
This study looks at how well a new anti-tumor drug works when given along with radiation therapy for people whose advanced breast cancer has spread to the brain. It may help the radiation work better and control the cancer longer.
Hear when a new Brain Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.